Modifying T cells before activation and expanding them in vitro may lead to more effective and safer immunotherapy treatments. If the challenges associated with resting T cell transfection can be overcome, scientists could use these cells in CAR T cell therapy, which could provide a significant reduction in time and materials required for production.
Download this application note from Thermo Fisher Scientific to learn about a nonviral cell engineering method for generating CAR T cells from resting, nonactivated T cells, using a shortened workflow.